Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 1998

View Archived Issues

Algene: Q4 and year-end 1997 highlights

CellPro: Q4 and FY 1998 highlights

Neoprobe receives patent allowance for its RIGS/ACT anticancer technology

Xoma granted two patents related to its BPI products

Enzon: Q3 1998 highlights

Glaxo Wellcome updates shareholders at AGM

ImmuLogic licenses antiallergy products from Sankyo

NPS Pharmaceuticals describes new drug development program

Synthelabo and Searle extend joint venture

RSR13 enhances effects of radiotherapy in patients with glioblastoma

PPD and Lilly join forces to develop genitourinary compounds

Multiple-dose pharmacokinetics/pharmacodynamics reported for ABT-761

5-HT4 derivative R-093877 enhances colonic transit in healthy volunteers

FDA says DepoCyt is not approvable

Bombesin receptor antagonists developed by Warner-Lambert

JTE-522 suppresses recurrent allergic inflammation in rats

RCT describes truncated chemokine analogues for rheumatoid arthritis

Antimicrobial peptide isolated from Korean frog

Improved MMR vaccine launched in U.K.

Bayer and Scios enter alliance for Natrecor

Fujisawa presents new cephalosporin with good anti-H. pylori activity

Controlled trial of thalidomide for mucocutaneous lesions of Behcet's syndrome

Phase I results presented for Sch-58500, Schering-Plough's p53-based cancer gene therapy

Ligand files NDA for Panretin gel

p38 kinase inhibitor protects against ischemic cell death in preclinical model

Glaxo Wellcome and NeXstar sign three-part collaboration; NeXstar in-licenses topo I inhibitor

Profile of antiarrhythmic activity of GYKI-16638, a new class Ib/III agent

New HIV protease inhibitors disclosed by Merck & Co.

P2T purinoceptor receptor antagonists with platelet antiaggregatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...